Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LIAN Stock Summary
Top 10 Correlated ETFs
LIAN
In the News

LianBio to Participate in Upcoming Investor Conferences
SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following upcoming investor conferences:

LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.

Penny Stocks To Buy Now? 6 To Watch With Big News Today
Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 To Watch As APE Stock Goes Public
Hot penny stocks to watch but are they a buy now or not? Let's look at the catalysts.

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

LianBio Stock (LIAN): Why The Price Surged Today
The stock price of LianBio (NASDAQ: LIAN) increased by 19.67% today. This is why it happened.

Medical Device Maker Highlights China Risk As Chinese U.S. IPOs Resume
Meihua International files updated prospectus highlighting China oversight risk in latest filing for its modest $57 million U.S. IPO.

China-U.S. IPO Pipeline Creaks Back To Life With 2 New Listing Plans
Two Chinese companies, drug maker LianBio and hotel operator Atour, are moving ahead with U.S. IPOs after a three-month pause on such listings.
LIAN Financial details
LIAN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | |
Net income per share | 0 | -1.33 | -5.71 | -1.02 | |
Operating cash flow per share | 0 | -0.93 | -4.77 | -0.92 | |
Free cash flow per share | 0 | -0.94 | -4.79 | -0.94 | |
Cash per share | 0 | 2.42 | 11.14 | 2.8 | |
Book value per share | 0 | -1.26 | 10.28 | 2.41 | |
Tangible book value per share | 0 | -0.93 | 11.26 | 2.72 | |
Share holders equity per share | 0 | -1.26 | 10.28 | 2.41 | |
Interest debt per share | 0 | 0.02 | 0.15 | -0.1 | |
Market cap | 0 | 1.44B | 211.87M | 176.99M | |
Enterprise value | -42.77M | 1.19B | -11.48M | 102.11M | |
P/E ratio | 0 | -10.33 | -1.08 | -1.6 | |
Price to sales ratio | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | -14.69 | -1.29 | -1.78 | |
PFCF ratio | 0 | -14.56 | -1.28 | -1.75 | |
P/B Ratio | 0 | -10.86 | 0.6 | 0.68 | |
PTB ratio | 0 | -10.86 | 0.6 | 0.68 | |
EV to sales | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | -8.83 | 0.06 | -0.81 | |
EV to operating cash flow | 0 | -12.12 | 0.07 | -1.03 | |
EV to free cash flow | 0 | -12.01 | 0.07 | -1.01 | |
Earnings yield | 0 | -0.1 | -0.93 | -0.62 | |
Free cash flow yield | 0 | -0.07 | -0.78 | -0.57 | |
Debt to equity | -0.03 | -0.01 | 0.01 | 0.02 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 0 | 1.87 | 1.14 | 0.6 | |
Current ratio | 12.96 | 44.45 | 26.48 | 13.24 | |
Interest coverage | 0 | 0 | -804.81 | 8.51 | |
Income quality | 0 | 0.7 | 0.84 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0.01 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -11.66 | -1.8 | -1.83 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
Graham number | 0 | 6.14 | 36.33 | 7.44 | |
ROIC | 0 | 1.04 | -0.54 | -0.47 | |
Return on tangible assets | 0 | -0.5 | -0.46 | -0.34 | |
Graham Net | 0 | -1.02 | 10.05 | 2.57 | |
Working capital | 40M | 270.52M | 384.56M | 289.16M | |
Tangible asset value | -14.82M | -98.07M | 387.34M | 293.65M | |
Net current asset value | -15.35M | -100.61M | 360.64M | 286.46M | |
Invested capital | -0.03 | -0.01 | 0.01 | 0.02 | |
Average receivables | 0 | 10.13M | 13.15M | 3.91M | |
Average payables | 0 | 2.16M | 3.78M | 2.34M | |
Average inventory | 0 | 0 | -3.02M | -3.02M | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 0 | 1.05 | -0.56 | -0.42 | |
Capex per share | 0 | -0.01 | -0.03 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.39 | -0.2 | -0.17 | -0.22 | -0.2 | |
Operating cash flow per share | -0.37 | -0.15 | -0.28 | -0.16 | -0.18 | |
Free cash flow per share | -0.37 | -0.16 | -0.29 | -0.16 | -0.18 | |
Cash per share | 3.05 | 2.88 | 2.8 | 2.67 | 2.49 | |
Book value per share | 2.71 | 2.52 | 2.4 | 2.25 | 2.07 | |
Tangible book value per share | 3.02 | 2.83 | 2.72 | 2.56 | 2.38 | |
Share holders equity per share | 2.71 | 2.52 | 2.4 | 2.25 | 2.07 | |
Interest debt per share | 0.06 | 0.06 | -0.07 | 0.01 | 0.03 | |
Market cap | 233.11M | 216.71M | 177.33M | 210.04M | 244.33M | |
Enterprise value | 104.24M | 142.61M | 102.45M | 111.62M | 143.58M | |
P/E ratio | -1.37 | -2.47 | -2.43 | -2.18 | -2.83 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -5.92 | -13.57 | -5.77 | -11.91 | -12.65 | |
PFCF ratio | -5.87 | -12.82 | -5.73 | -11.9 | -12.62 | |
P/B Ratio | 0.8 | 0.79 | 0.68 | 0.87 | 1.1 | |
PTB ratio | 0.8 | 0.79 | 0.68 | 0.87 | 1.1 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.42 | -5.88 | -3.5 | -4.35 | -5.73 | |
EV to operating cash flow | -2.65 | -8.93 | -3.34 | -6.33 | -7.43 | |
EV to free cash flow | -2.62 | -8.44 | -3.31 | -6.32 | -7.41 | |
Earnings yield | -0.18 | -0.1 | -0.1 | -0.11 | -0.09 | |
Free cash flow yield | -0.17 | -0.08 | -0.17 | -0.08 | -0.08 | |
Debt to equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 3 | 3.05 | 2.56 | 3.84 | 4.02 | |
Current ratio | 15.8 | 14.72 | 13.24 | 11.42 | 12.62 | |
Interest coverage | -78.01 | -17.47 | 2.42 | 10.99 | 0 | |
Income quality | 0.93 | 0.73 | 1.68 | 0.73 | 0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.06 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -2.38 | -3.35 | -0.74 | -0.06 | -0.15 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.89 | 3.38 | 3.02 | 3.37 | 3.06 | |
ROIC | -0.14 | -0.09 | -0.11 | -0.11 | -0.11 | |
Return on tangible assets | -0.11 | -0.06 | -0.06 | -0.08 | -0.08 | |
Graham Net | 2.69 | 2.53 | 2.57 | 2.42 | 2.28 | |
Working capital | 321.96M | 302.21M | 289.16M | 270.13M | 251.46M | |
Tangible asset value | 326.2M | 306.6M | 293.65M | 274.43M | 255.51M | |
Net current asset value | 298.09M | 278.99M | 286.46M | 267.89M | 249.81M | |
Invested capital | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Average receivables | 9.04M | 9.18M | 5.63M | 2.86M | 2.49M | |
Average payables | 4.58M | 1.63M | 1.74M | 3.44M | 3.67M | |
Average inventory | 0 | 0 | 0 | -1.98M | -1.98M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.14 | -0.08 | -0.07 | -0.1 | -0.1 | |
Capex per share | 0 | -0.01 | 0 | 0 | 0 |
LIAN Frequently Asked Questions
What is LianBio stock symbol ?
LianBio is a US stock , located in Princeton of Nj and trading under the symbol LIAN
What is LianBio stock quote today ?
LianBio stock price is $1.4999 today.
Is LianBio stock public?
Yes, LianBio is a publicly traded company.